

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Calcium chloride hydrate (injection excluding preparations indicated for electrolyte correction in electrolyte replacement fluids)

April 21, 2026

### **Therapeutic category**

Calcium compounds and preparations

### **Non-proprietary name**

Calcium chloride hydrate (injection)

### **Safety measure**

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.  
 This English version is intended to be a reference material to provide convenience for users.  
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

| Current   | Revision   |   |                               |   |                                  |   |   |       |                                |                        |  |  |   |
|---|--|---|-------------------------------|---|----------------------------------|---|---|-------|--------------------------------|------------------------|--|--|---|
| <p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)<br/> <u>Patients receiving digitalis preparations (digoxin, etc.)</u></p> <p>10. INTERACTIONS<br/> <u>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</u></p> <table border="1" data-bbox="241 679 1090 924"> <thead> <tr> <th data-bbox="241 679 468 778"><u>Drugs</u></th> <th data-bbox="470 679 779 778"><u>Signs, symptoms, and treatment</u></th> <th data-bbox="781 679 1090 778"><u>Mechanism/risk factors</u></th> </tr> </thead> <tbody> <tr> <td data-bbox="241 780 468 924"><u>Digitalis preparations</u><br/><u>Digoxin, etc.</u></td> <td data-bbox="470 780 779 924"><u>Cardiac arrest may occur.</u></td> <td data-bbox="781 780 1090 924"><u>The effects of the digitalis preparations may be enhanced.</u></td> </tr> </tbody> </table> <p>10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)</p> <p>(N/A)</p> | <u>Drugs</u>   | <u>Signs, symptoms, and treatment</u>                               | <u>Mechanism/risk factors</u> | <u>Digitalis preparations</u><br><u>Digoxin, etc.</u> | <u>Cardiac arrest may occur.</u> | <u>The effects of the digitalis preparations may be enhanced.</u> | <p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)<br/>                     (Deleted)</p> <p>10. INTERACTIONS<br/>                     (Deleted)</p> <p>10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)</p> <table border="1" data-bbox="1135 1066 2004 1398"> <thead> <tr> <th data-bbox="1135 1066 1391 1163">Drugs</th> <th data-bbox="1393 1066 1762 1163">Signs, symptoms, and treatment</th> <th data-bbox="1765 1066 2004 1163">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="1135 1165 1391 1398"><u>Cardiac glycosides</u><br/><u>Metildigoxin</u><br/><u>Digoxin</u><br/><u>Deslanoside</u></td> <td data-bbox="1393 1165 1762 1398"><u>The effects of cardiac glycosides may be enhanced to induce toxic symptoms such as bradycardia, ventricular</u></td> <td data-bbox="1765 1165 2004 1398"><u>Calcium enhances the cardiac contractility-enhancing effects</u></td> </tr> </tbody> </table> | Drugs | Signs, symptoms, and treatment | Mechanism/risk factors | <u>Cardiac glycosides</u><br><u>Metildigoxin</u><br><u>Digoxin</u><br><u>Deslanoside</u> | <u>The effects of cardiac glycosides may be enhanced to induce toxic symptoms such as bradycardia, ventricular</u> | <u>Calcium enhances the cardiac contractility-enhancing effects</u> |
| <u>Drugs</u>  | <u>Signs, symptoms, and treatment</u>  | <u>Mechanism/risk factors</u>                                       |                               |   |                                  |   |   |       |                                |                        |  |  |   |
| <u>Digitalis preparations</u><br><u>Digoxin, etc.</u>   | <u>Cardiac arrest may occur.</u>   | <u>The effects of the digitalis preparations may be enhanced.</u>   |                               |   |                                  |   |   |       |                                |                        |  |  |   |
| Drugs   | Signs, symptoms, and treatment   | Mechanism/risk factors  |                               |   |                                  |   |   |       |                                |                        |  |  |   |
| <u>Cardiac glycosides</u><br><u>Metildigoxin</u><br><u>Digoxin</u><br><u>Deslanoside</u>  | <u>The effects of cardiac glycosides may be enhanced to induce toxic symptoms such as bradycardia, ventricular</u> | <u>Calcium enhances the cardiac contractility-enhancing effects</u> |                               |   |                                  |   |   |       |                                |                        |  |  |   |

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

|  |  |   |
|--|--|---|
|  | <p><u>extrasystoles,</u><br/><u>atrioventricular block, and</u><br/><u>ventricular tachycardia.</u><br/><u>Cardiac arrest may occur.</u><br/><u>Co-administration with these</u><br/><u>drugs should be avoided</u><br/><u>unless it is considered</u><br/><u>therapeutically essential. If</u><br/><u>co-administration is</u><br/><u>inevitable, monitoring using</u><br/><u>an electrocardiogram, etc.</u><br/><u>should be performed to deal</u><br/><u>with the occurrence of</u><br/><u>arrhythmia. In addition,</u><br/><u>usage in such a way as to</u><br/><u>rapidly increase calcium</u><br/><u>concentration should be</u><br/><u>avoided.</u></p> | <p><u>of cardiac</u><br/><u>glycosides.</u></p> |
|--|--|---|

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*